rich 1.0 Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Grace Gombolay, MD, associate professor of pediatrics at Emory University School of Medicine and director of the Pediatric Neuroimmunology and Multiple Sclerosis Program at Children's Healthcare of Atlanta, joins Varun Kannan, MD, assistant professor of pediatrics in the Department of Neurology at Emory University School of Medicine and Children's Healthcare of Atlanta, for a discussion on acute disseminated encephalomyelitis (ADEM), a rare inflammatory demyelinating syndrome that remains an important diagnostic consideration in pediatric neuroimmunology. The conversation provides a practical overview of how clinicians should recognize ADEM, distinguish it from conditions such as multiple sclerosis, MOG antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), and approach treatment in the absence of FDA-approved therapies. Gombolay and Kannan review the clinical and radiographic hallmarks of ADEM, the role of MRI and antibody testing in the diagnostic workup, and current treatment strategies involving corticosteroids, IVIG, and plasma exchange. They also discuss long-term outcomes, the evolving relationship between ADEM and MOGAD, emerging biomarkers such as neurofilament light chain and cytokine profiling, and common misconceptions that can complicate diagnosis and management in clinical practice. Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page (https://www.neurologylive.com/clinical/ms) . Episode Breakdown: 1:15 – Recognizing the clinical and imaging features of ADEM 3:30 – Distinguishing ADEM from MS, MOGAD, and NMOSD 7:20 – Current treatment approaches and management strategies 10:10 – Neurology News Network 12:40 – Long-term outcomes and monitoring after recovery 15:55 – Emerging biomarkers and improving diagnostic precision 19:10 – Preventing future attacks and reducing relapse risk 21:10 – Remaining research gaps and unanswered questions in ADEM The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway (https://www.neurologylive.com/view/fda-allows-amt-130-huntington-disease-data-support-planned-bla-submission-under-accelerated-approval-pathway) Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade (https://www.neurologylive.com/view/teva-submits-nda-ecopipam-potential-first-new-tourette-syndrome-treatment-over-decade) FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis (https://www.neurologylive.com/view/fda-ema-accepts-regulatory-applications-cemdisiran-generalized-myasthenia-gravis) Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com (http://neurologylive.com/) . NeurologyLive® Mind Moments® https://audioboom.com/channels/5001429-neurologylive-mind-moments Audioboom https://audioboom.com 480 95 https://audioboom.com/i/39490422/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8920566/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>